Bluesky Facebook Reddit Email

VAI study rules out transcriptional coactivators as useful herpes antiviral drug targets

03.25.09 | Van Andel Research Institute

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Grand Rapids, Mich. (March 25, 2009) – Researchers at Van Andel Research Institute (VARI) have determined that the herpes simplex virus type 1 (HSV-1) does not require transcriptional coactivators for viral gene expression early in the infection process. The finding is significant in determining that, in contradiction to earlier models, chemical inhibitors of these cellular proteins are not likely to serve as useful antiviral drugs.

Researchers sought to determine how herpes simplex virus "turns on" its viral genes during the first stages of infection. Specifically, they tested whether the expression of the viral genes would be similar to how cellular genes are turned on, and specifically whether the viral genes would depend on a set of cellular proteins called "coactivators."

"Based on an earlier model we expected that expression of the viral genes would depend on a set of transcriptional coactivators," said Scientific Investigator Steve Triezenberg, Ph.D., head of the VARI Laboratory of Transcriptional Regulation and co-author of the study published in a recent issue of the Journal of Virology . "As it turns out, we got an unexpected answer. Using several different approaches, we consistently saw that the coactivator proteins are not required for viral gene expression."

Researchers have understood that virion protein 16 (VP16) of herpes simplex virus type 1 is a potent transcriptional activator of viral immediate early (IE) genes. However, the role of transcriptional coactivators had not been fully understood.

"This is a significant finding because it tells us that chemical inhibitors of these coactivators are not likely to be good antiviral drugs, despite our earlier model," said Triezenberg.

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. www.vai.org

Journal of Virology

Keywords

Article Information

Contact Information

Source

How to Cite This Article

APA:
Van Andel Research Institute. (2009, March 25). VAI study rules out transcriptional coactivators as useful herpes antiviral drug targets. Brightsurf News. https://www.brightsurf.com/news/80V5OEXL/vai-study-rules-out-transcriptional-coactivators-as-useful-herpes-antiviral-drug-targets.html
MLA:
"VAI study rules out transcriptional coactivators as useful herpes antiviral drug targets." Brightsurf News, Mar. 25 2009, https://www.brightsurf.com/news/80V5OEXL/vai-study-rules-out-transcriptional-coactivators-as-useful-herpes-antiviral-drug-targets.html.